Status:
UNKNOWN
A Study of Gene Polymorphisms and Normal Tissue Radiation Injury in Patients Treated for Breast, Prostate, Brain, Lung, and Head and Neck Cancers
Lead Sponsor:
AHS Cancer Control Alberta
Collaborating Sponsors:
Cross Cancer Institute
Conditions:
Breast Cancer
Glioma
Eligibility:
All Genders
Brief Summary
This study will examine, for the first time, the independent contribution of a patient's own genetic makeup to the development of post-radiation complications, permitting the future development of pre...
Detailed Description
Major innovations in radiotherapy (RT) delivery (3D conformal RT, intensity modulated RT) now permit RT dose escalation to be tested as a means of improving disease control in many tumour sites. With ...
Eligibility Criteria
Inclusion
- Breast cancer
- Prostate cancer
- Squamous cell carcinoma (SCC) of the head and neck
- Non-small-cell-lung carcinoma (NSCLC)
- Glioma treated by radiotherapy
Exclusion
- Follow-up less than 18 months
Key Trial Info
Start Date :
January 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2017
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00122239
Start Date
January 1 2005
End Date
February 1 2017
Last Update
March 16 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2